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The  efﬁcacy  of  vaccines  is typically  estimated  prior to  implementation,  on  the  basis  of  random-
ized  controlled  trials.  This  does  not  preclude,  however,  subsequent  assessment  post-licensure,  while
mass-immunization  and  nonlinear  transmission  feedbacks  are  in  place.  In  this  paper  we  show  how
cross-sectional  prevalence  data  post-vaccination  can  be interpreted  in  terms  of  pathogen  transmis-
sion  processes  and  vaccine  parameters,  using  a dynamic  epidemiological  model.  We  advocate  the use  of
such frameworks  for model-based  vaccine  evaluation  in  the  ﬁeld,  ﬁtting trajectories  of cross-sectional
prevalence  of pathogen  strains  before  and  after  intervention.  Using  SI and  SIS  models,  we  illustrate  how
prevalence  ratios  in  vaccinated  and  non-vaccinated  hosts  depend  on true vaccine  efﬁcacy,  the  absolute
and  relative  strength  of  competition  between  target  and  non-target  strains,  the time  post  follow-up,
and  transmission  intensity.  We  argue  that a mechanistic  approach  should  be  added  to vaccine  efﬁcacyDE parameter inference estimation  against  multi-type  pathogens,  because  it naturally  accounts  for  inter-strain  competition  and
indirect  effects,  leading  to a robust  measure  of individual  protection  per  contact.  Our study  calls  for  sys-
tematic  attention  to epidemiological  feedbacks  when  interpreting  population  level  impact.  At  a  broader
level,  our  parameter  estimation  procedure  provides  a promising  proof  of  principle  for  a generalizable
framework  to infer vaccine  efﬁcacy  post-licensure.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Mathematical epidemiological models for the dynamics of
icroparasite infections have a long history of development and
se in the design and optimization of intervention programmes
Anderson et al., 1992). Yet, many challenges remain in applying
uch models retrospectively to interpret and quantify interven-
ion effects in host–pathogen systems (Keeling, 2005; O’Hagan
t al., 2014; Wikramaratna et al., 2014; Goeyvaerts et al., 2015).
t is of public interest to quantify the relative effectiveness of
ifferent control strategies, assess the ongoing changes in trans-
ission dynamics following such interventions, and optimize their
esign through a cost–beneﬁt analysis for the future. In this paper,
ur focus is on vaccination as a transmission-reducing interven-
ion, and more speciﬁcally, in the context of endemic pathogens.
lthough the amount of data available from epidemiological trials,
∗ Corresponding author.
E-mail address: egjini@igc.gulbenkian.pt (E. Gjini).
ttp://dx.doi.org/10.1016/j.epidem.2015.11.001
755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cross-sectional and longitudinal surveys is vast and rapidly increas-
ing, our understanding and interpretation of such data on the
basis of transmission mechanisms and epidemiological feedbacks
is limited. This is apparent for many pathogen systems, includ-
ing Streptococcus pneumoniae bacteria, human papillomaviruses,
dengue, malaria, inﬂuenza and rotaviruses. Currently several vac-
cines are being used or contemplated to control these pathogens
around the world (Comanducci et al., 2002; Insinga et al., 2007; del
Angel and Reyes-del Valle, 2013; Sabchareon et al., 2012; Agnandji
et al., 2011; Black et al., 2000), and assessing their efﬁcacy is
crucial.
Conceptual models can play a key role in this assessment, ﬁrst by
clearly deﬁning the measures of interest, secondly, by distinguish-
ing individual from population indicators, and thirdly, by enabling
us to anticipate future outcomes of vaccination programmes. An
important vaccine parameter is efﬁcacy against pathogen acquisi-
tion, deﬁned as reduction in the probability of infection per contact
of each vaccinated individual (Haber et al., 1991). Before a vaccine
is introduced, vaccine efﬁcacy estimation is typically performed
through randomized controlled trials, involving a subset of a given
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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opulation (Halloran et al., 2010). Such vaccine evaluation studies
se 1 − RR (1 minus risk ratio), as a measure of efﬁcacy, where RR is
ome estimate of relative risk in vaccinated vs. non-vaccinated indi-
iduals. This tends to ignore indirect effects (Halloran et al., 1991),
uch as the changes in transmission mediated by the intervention,
hich while in the time and coverage of trials are indeed expected
o be negligible, are not quite negligible when mass-immunization
s in place (Shim and Galvani, 2012).
The assessment of vaccines post-licensure is also of interest, and
ere is where dynamic mathematical models can be useful, along-
ide statistical approaches (Biondi and Weiss, 2015; Crowe et al.,
014; Andrews et al., 2014). There are several reasons for why  such
-posteriori assessment is important. First, only a dynamic model
an properly link pre-licensure vaccine expectations and observed
utcomes in a population undergoing immunization, thereby pro-
iding a validity test for the numerical estimates of vaccine efﬁcacy
btained from trials, and a validity test for the public-health pro-
ections made a priori regarding effectiveness, or population level
mpact. Second, only a dynamic model can take into account in a
echanistic manner the time since the onset of the vaccination
rogramme, regardless of equilibrium requirements (Rinta-Kokko
t al., 2009), and consider the actual vaccine coverage in a given
etting. Third, in the context of multi-strain pathogens, where mul-
ivalent vaccines target a subset of pathogen types, only a dynamic
odel can properly implement the nonlinear interactions between
athogen types (Lipsitch, 1997; Martcheva et al., 2008), arising
hrough direct competition, cross-immunity or asymmetric vaccine
rotection.
Although there has been recognition of the importance of
ynamic transmission models for vaccine assessment (Shim and
alvani, 2012), few studies so far have attempted to infer vaccine
fﬁcacy ﬁtting dynamic models to temporal prevalence trajecto-
ies post-vaccination (Choi et al., 2011; Gjini et al., 2016). Other
pproaches have suggested that prevalence odds ratios may  be
ore suitable than prevalence ratios to determine vaccine efﬁcacy,
nd that special attention must be given to the time of sampling
ost-vaccination (Scott et al., 2014). Another study by Omori et al.
2012) has used dynamic models (SIS and SIR) to illustrate the
ias in odds-ratio estimators of vaccine efﬁcacy for two  compet-
ng pathogen types, but their estimation was based on prevalences
t endemic steady state only, posing a strong restriction on the
ethod. A recent study by van Boven et al. (2013) deals with
accine efﬁcacy estimation in an epidemic scenario, and applies
 dynamic modelling framework to mumps  outbreak data in the
etherlands.
Here, we advocate a similar dynamic spirit in the context
f endemic diseases. We  propose a novel approach to vaccine
fﬁcacy estimation using cross-sectional prevalence data inte-
rated within dynamic mathematical models. This enables a deeper
nderstanding of vaccine performance in the ﬁeld, as mediated by
ransmission intensity, competition between pathogen subtypes
nd host factors. When vaccine coverage is high, the transmis-
ion cycle encompasses vaccinated and non-vaccinated individuals
nteracting through contact, thus affecting and being subject to
 dynamic force of infection. With a gradually diminishing expo-
ure to vaccine types, in polymorphic systems, subtype relative
requencies can change in the population from the combined effects
f vaccination and interactions between target and non-target
athogen types. If a vaccine induces a replacement phenomenon,
s it has been argued for pneumococcus (Weinberger et al., 2011)
nd HPV (Biondi and Weiss, 2015), vaccine efﬁcacy against targeted
athogen strains, can be estimated while these strains are still in
irculation, namely while type replacement is not yet complete,
nd sufﬁcient information can be extracted. It is precisely in this
ntermediate dynamic phase that most vaccine observational stud-
es are conducted, and where epidemiological feedbacks, includingmics 14 (2016) 71–82
changes in exposure and interaction between multiple strains, are
most likely to play a role.
To correctly capture all these processes, more reﬁned math-
ematical frameworks are needed. This requires going beyond
direct statistical comparisons, based on static data, e.g. snap-
shot prevalence odds ratios from observational studies (Thompson
et al., 1998), or the indirect cohort method for case–control data
(Andrews et al., 2011), which neglects pathogen subtype interfer-
ence altogether. Even more importantly, the cohort method fails
to acknowledge that the probability of infection of an individual
depends on the infection prevalence in the population, i.e. on the
infection status of others.
With a dynamic modelling approach, instead, the problem of
constant hazard ratios (Hernán, 2010) can be circumvented, as can
limitations of the indirect cohort method (Moberley and Andrews,
2014) for purposes of vaccine efﬁcacy estimation. Furthermore,
data can be interpreted relaxing the stationarity requirement and
accounting for pathogen type replacement. Other statistical esti-
mation methods such as incidence density sampling (Richardson,
2004), might also not require the assumption of stationarity, but
they do not deal with competition in multi-strain pathogen sys-
tems.
The deﬁnition of vaccine efﬁcacy that we consider in this paper
has a clear biological meaning: reduction of the probability of
pathogen acquisition per contact, which enables extrapolation
beyond a single study population. This contrasts classical estimates
of vaccine efﬁcacy that are based on comparing attack rates in vac-
cinated and unvaccinated individuals (the cohort method), or those
that use the vaccination status of the infected individuals relative to
the population vaccination coverage (the screening method). Such
vaccine efﬁcacy indicators lack a clear biological meaning, which
makes interpretation problematic, and prevents anticipation of the
critical vaccination coverages needed to reach certain desired out-
comes.
In this study, we argue that temporal effects of vaccination pro-
grammes can be addressed through dynamic mathematical models,
where parameters of efﬁcacy are explicitly deﬁned in terms of
underlying transmission mechanisms, and where epidemiologi-
cal feedbacks among immunized and non-immunized individuals,
and between pathogen strains are correctly accounted for. In the
interest of simplicity and clarity, we  only consider minimal epi-
demiological models to illustrate vaccine effects on single and
multiple infection with different pathogen types, but the uncovered
trends should apply in similar vein to more complex vaccination
scenarios (Halloran et al., 1991, 2010). We  delineate a proof-
of-concept inference procedure, based on ODE model ﬁtting, to
cross-sectional data collected over different time points after vac-
cine implementation.
2. Materials and methods
To build intuition in our reader, initially we present susceptible-
infected (SI) model frameworks accounting for one and two
pathogen types, while the susceptible-infected-recovered (SIR)
analogues are elaborated in the Supplementary Text S2. Then
we proceed to susceptible-infected-susceptible (SIS) models with
many-type pathogens, grouped according to whether they are tar-
geted by a polyvalent vaccine or not. We  always assume that the
vaccine is effective against type 1 pathogen (SI/SIR models), or
against pathogen subtypes in group 1 (SIS setting). The mode of
action of the vaccine we consider is leaky (Halloran et al., 1991),
and the vaccine efﬁcacy is deﬁned as the reduction in probabil-
ity of infection/pathogen acquisition per contact. Notice that in
this paper, we will use the terms ‘infection’ and ‘carriage’ inter-
changeably. As the source of prevalence data, we  consider active
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urveillance programmes pre- and post-vaccination in a popula-
ion, whereby the carriage status and pathogen type(s) of each
creened individual are determined. The basic structure of the mod-
ls in the absence of an intervention is given in Fig. 1.
.1. SI model – 1 pathogen type (n = 1)
The ﬁrst model we consider for illustration is a simple
usceptible-infected model with one pathogen type that is directly-
ransmitted (SI-1). With a continuous vaccination programme in
lace, the proportions of hosts in different compartments are given
y:
Non-vaccinated hosts
dS0
dt
= (1 − ) − ˇS0(I0 + I1) − S0
dI0
dt
= ˇS0(I0 + I1) − I0
⎧⎪⎪⎨
⎪⎪⎩
Vaccinated hosts
dS1
dt
=  − ˇwS1(I0 + I1) − S1
dI1
dt
= ˇwS1(I0 + I1) − I1
here subscripts 0 and 1 indicate non-vaccinated and vaccinated
ost status, respectively. The parameter  ˇ is the per-capita trans-
ission coefﬁcient and  the birth rate (equal to the death rate).
osts are born with a life expectancy of 1/. The vaccination cov-
rage at birth is  and vaccine efﬁcacy is given by 1 − w, assuming
 homogeneous effect (leaky vaccine). In the absence of a vac-
ine, for such pathogen to persist, the basic reproduction number
Heesterbeek, 2000) R0 = ˇ/ must exceed 1, and the higher R0 is,
he higher the pathogen prevalence.
.2. SI model with 2 competing pathogen types (n = 2)
Extending the above model to two pathogen types (SI-2), we
ave:
Non-vaccinated hosts
dS0
dt
= (1 − ) − (1 + 2)S0 − S0
dI01
dt
= 1S0 − I0112 − I01
dI02
dt
= 2S0 − I0221 − I02
dI012
dt
= 12I01 + 21I02 − I012
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
Vaccinated hosts
dS1
dt
=  − (w1 + 2)S1 − S1
dI11
dt
= w1S1 − I1112 − I11
dI12
dt
= 2S1 − I122w1 − I12
dI112
dt
= 12I11 + 2w1I12 − I112,
here  = ˇ(I0 + I0 /2 + I1 + I1 /2) and  = ˇ(I0 + I0 /2 + I1 +1 1 12 1 12 2 2 12 2
1
12/2). The above equations track the proportions of non-
accinated and vaccinated hosts in 4 classes: susceptibles, S, hosts
arrying pathogen type 1, I1, hosts carrying pathogen type 2, I2,
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
Non-vaccinated hosts
dS0
dt
= (1 − ) − (1 + 2 + )S0 + 
dI01
dt
= 1S0 − I01(2 + 1) − ( + 
dI20
dt
= 2S0 − I02(1 + 2) − ( +
dI011
dt
= 1I01 − ( + )I011
dI022
dt
= 2I02 − ( + )I022
dI012
dt
= (2I01 + 1I02) − ( + )I012mics 14 (2016) 71–82 73
and co-infected hosts I12, where S0 +
∑
I0 = 1 −  and S1 +∑I1 = 
respectively for non-vaccinated and vaccinated host compart-
ments. Overall we have: S +
∑
I = 1. Upon primary pathogen
exposure, a susceptible host can acquire pathogen type 1 or type
2. The forces of infection (FOI) depend explicitly on prevalence:
1(t) for type 1, and 2(t) for type 2. Single carriers block sub-
sequent acquisition of the same type but can acquire the other
pathogen type with a reduced rate i, this due to competition
between the resident and the newcomer strain. Assuming no clear-
ance, there is an endemic persistence equilibrium whenever  ˇ > 
in the absence of intervention ( = 0). Stable coexistence between
types requires further constraints on 1 and 2, as shown in
Fig. S1.
2.3. SIS model for 2 groups of pathogen types (n  2)
For pathogens with larger antigenic diversity, many types
can circulate simultaneously in a host population. The con-
stituent pathogen subtypes can be equivalent in most life-history
traits, including basic transmission and clearance potential. How-
ever, when vaccination with polyvalent vaccines is considered, it
becomes practical to aggregate them into types of group 1, (vac-
cine types, i.e. those that will be targeted by an intervention), and
group 2 (remaining ones, or non-vaccine types). Typically a host
may  acquire any pathogen type of group 1, or group 2, or be a dou-
ble carrier of two  types: from group 1, from group 2, or one of
each.
Acquisition of a second pathogen type generally occurs at a
reduced rate compared to single carriage, due to direct competition
between the resident and newcomer pathogen types. Competition
between any two pathogen types is represented by parameter  < 1.
When they belong to the same group we apply an extra reduction
factor  to account for the fact that there is one less type available
for colonization within the same group. In this sense  should be
seen as a factor representing depletion of available types, which
can exert a small or large effect on coinfection by types within the
same group, depending on whether the group has many types or
just a few.
Although in principle any individual carriage episode can induce
some type-speciﬁc immunity, we consider the magnitude of such
immunity negligible when assessed on the entire pool of all
pathogen types from the parent group. There is, however, noth-
ing to preclude the inclusion of cumulative immunity in model
extensions informed by data on speciﬁc pathogens. Meanwhile,
we are effectively working with SIS epidemiological dynamics at
the level of groups of subtypes. The system with vaccination is
given by:
(1 −  − S0)
)I01
 )I02
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪
Vaccinated hosts
dS1
dt
=  − (w1 + 2)S1 − S1 + ( − S1)
dI11
dt
= w1S1 − I11(2 + w1) − ( + )I11
dI12
dt
= 2S1 − I12(w1 + 2) − ( + )I12
dI111 1 1⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
dt
= w1I1 − ( + )I11
dI122
dt
= 2I12 − ( + )I122
dI112
dt
= (2I11 + w1I12) − ( + )I112,
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PR∗ = I
1∗/
I0∗/(1 − )ig. 1. Model diagrams in the absence of vaccination. The direct competition phen
ate  of transition from single to dual colonization.
here the parameter  denotes the clearance rate of each carriage
pisode, assumed equal for single and dual carriage, as in some
neumococcus models (Colijn et al., 2009; Mitchell et al., 2015). The
orces of infection are: 1 = ˇ(I01 + I011 + I012/2 + I11 + I111 + I112/2)
nd 2 = ˇ(I02 + I022 + I012/2 + I12 + I122 + I112/2). In this formulation,
s well as in the SI-2 formulation, it is assumed that an individual
arrying two pathogen subtypes is only 50% infectious for either
ne of them, a special case of neutral null models (Lipsitch et al.,
009).
Stability of the endemic equilibrium in the absence of interven-
ion requires R0 = ˇ/( + ) > 1. A condition for stable coexistence of
he two groups of pathogen subtypes in the absence of intervention
s that  < 1, which is always true given the meaning of . As in the
revious models, we assume that a fraction  of the population is
accinated, with a vaccine that reduces susceptibility to targeted
athogen types (here group 1) by a factor w (0 ≤ w ≤ 1). The model
an be generalized to include ﬁner scales of competition between
athogen types, if important asymmetries happen to be implied by
peciﬁc pathogen data.
.4. Inferring vaccine efﬁcacy
In all our transmission models, vaccine efﬁcacy is given by
E = 1 − w, varying between 0 and 1, denoting the reduction
n probability of pathogen acquisition per contact in vacci-
ated individuals relative to those non-vaccinated (Haber et al.,
991). We  explore these models, with relation to retrospec-
ive analyses of cross-sectional prevalence data post-vaccination.
uch data may  be available through active sampling in obser-
ational studies of populations subject to mass-immunization,
nd we assume they reﬂect pathogen carriage irrespective of
ymptoms.
We initially generate cross-sectional prevalence data post-
accination through numerical simulation of model systems with
xed parameters. We  go on to compare the ratio of target pathogen
revalence (type 1 or group 1) in vaccinated vs. non-vaccinated
osts, with the true relative risk w, and we systematically show
ow the discrepancy between the two varies with time of obser-
ation, with transmission intensity and competition parameters
etween pathogen subtypes. This is performed for the SI-2 and SIS-
 models (but see Supplement Text S2 for an SIR-2 formulation).
hat we propose as a solution is to ﬁt the full dynamic model with
accination to prevalence trajectories, and infer in this way  vac-
ine efﬁcacy, simultaneously with other parameters. Notice that
his approach is different from the one suggested by Scott et al.
2014), where they advocate that snapshot prevalence ratio itself,
r prevalence-odds ratio be used, only at appropriate times post-
accination. Here we are not proposing a direct use of any static
bservation but rather a dynamic model ﬁt to multiple temporal
bservations of relative and absolute prevalence of carriage post-
accination.on between pathogen subtypes is represented by the grey arrows, modifying the
To motivate this approach, we  illustrate the discrepancy
between prevalence ratio and vaccine efﬁcacy. Thus, we  begin by
providing analytical insight using the simpler SI-1 model, where
it is easy to derive endemic prevalence equilibria pre- and post-
vaccination. Subsequently we explore numerically the models with
strain competition.
3. Results
3.1. Vaccine efﬁcacy and endemic equilibria of the SI-1 model
Pathogen carriage prevalence at the stable endemic equilibrium
in the absence of vaccination (Section 2.1,  = 0) is given by I∗pre =
1 − 1/R0, where R0 = ˇ/. In the presence of vaccination ( > 0), by
setting the differential equations to zero, we can compute the new
endemic equilibrium post-vaccine:
I∗ = w(R0 − 1) − 1 +
√
4(1 − )R0(1 − w)w + [w(R0 + 1) − 1]2
2R0w
.
(1)
Prevalence post-vaccine becomes clearly a nonlinear function of
basic reproductive number R0, vaccine efﬁcacy (1 − w), and cov-
erage  (Fig. 2a). When the coverage is perfect  = 1, we have
I∗ = 1 − (1/R0w). One can see for example that to eliminate the
pathogen, with perfect coverage, w needs to be higher than 1/R0,
or with imperfect coverage, the fraction vaccinated  and individual
vaccine protection w can be jointly traded-off against one another
in different critical combinations (i.e. those that satisfy I* = 0, in Eq.
(1)).
These analytical expressions also illustrate that if we  know
the endemic prevalence equilibria pre- and post-vaccine, and the
vaccination coverage , we can infer simultaneously R0 and w,
hence vaccine efﬁcacy (1 − w), by comparing pre-vaccine with
post-vaccine cross-sectional prevalence of carriage. The above
expression can be used to asses the ‘overall’ effectiveness of a vac-
cination program, deﬁned as the reduction in the transmission rate
for an average individual in a population with a vaccination pro-
gram at a given level of coverage compared to an average individual
in a comparable population with no vaccination program (Halloran
et al., 1991; Halloran, 2006).
Similarly, if we are interested in the relative equilibrium preva-
lence ratio (PR*) of infection in vaccinated and non-vaccinated
hosts, we can also obtain it analytically from the model:= −1 + w − R0w(1 − 2) +
√
4(1 − )R0(1 − w)w + [w(R0 + 1) − 1]2
2R0w
,
(2)
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Fig. 2. Infection prevalence at post-vaccination equilibrium vs. transmission intensity (SI-1 model). (A) Absolute prevalence of carriage. (B) Relative prevalence ratio in
vaccinated vs. non-vaccinated hosts. The different lines from top to bottom correspond to different values assumed for vaccine efﬁcacy (VE = 1 − w = 50%, 90%) while
keeping  ﬁxed coverage  = 0.5. The ratio of relative infection prevalence in vaccinated vs. non-vaccinated individuals at equilibrium does not reﬂect the same value of relative
risk  (w = 1 − VE) as transmission intensity R0 changes. While in this ﬁgure, all the points along each line reﬂect scenarios with the same vaccine efﬁcacy, the prevalence ratio
observed is different for each transmission intensity R0. This shows that one cannot simply translate 1 − prevalence ratio at equilibrium to a directly interpretable measure
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af  vaccine efﬁcacy, as deﬁned by the 1 − w parameter, encapsulating the instantan
mit  analysis of the corresponding SIS-1 type system, as the results are identical to
hich reveals that this quantity varies not only with the vaccine
arameters  and w, but also with transmission intensity, here rep-
esented by R0 (Fig. 2b). This analytical result clearly states that
revalence ratio, even at equilibrium, is unsuitable as a direct indi-
ator of vaccine efﬁcacy, as previously noted (Haber et al., 1991;
him and Galvani, 2012). In fact, PR* is commonly greater than w
xcept for special tripartite combinations of (R0, , w). Nonethe-
ess, it is precisely such nonlinear relationship between R0, vaccine
fﬁcacy, and prevalence, that lies at the heart of typical vaccination
rogrammes against childhood diseases (typically characterized by
IR dynamics), where the critical vaccination coverage needed to
liminate a pathogen has been determined through mathemati-
al models, and applied to control measles, smallpox, mumps, and
ubella.
Interestingly, when considering another ratio in our epi-
emiological model, namely the prevalence odds ratio (POR), at
quilibrium post-vaccine we get:
OR∗ = I
1∗/S1∗
I0∗/S0∗
= w, (3)
onﬁrming the classical result that the prevalence-odds-ratio, at
east in a simple SI-1 setting, is a perfect estimator of true relative
isk, provided we are at equilibrium. This has been shown previ-
usly by studies comparing prevalence ratios and prevalence-odds
atios (Greenland, 1987; Strömberg, 1994; Thompson et al., 1998).
Next, we brieﬂy address how in polymorphic pathogen systems,
he relationship between w and prevalence ratio depends system-
tically also on the strength of competition between pathogen
ypes, and ﬁnalize with our proposal to infer w as a fundamental
arameter of a dynamic model that can be ﬁtted to cross-sectional
ata pre- and post-vaccination.
.2. When prevalence ratio post-vaccination is modulated by
train competition and replacementHere we consider the effects of subtype competition in pathogen
ystems with many strains. We  simulate hypothetical vaccination
cenarios using the dynamic SI-2 and SIS-2 models (Sections 2.2
nd 2.3) with two interacting strains or groups of strains for T timeer-unit exposure protection factor experienced by each vaccinated individual. We
-1 model.
units post-vaccination. Time is measured in same units as host life
expectancy 1/. Focusing on the pathogen types targeted by the
vaccine, and neglecting the contribution of dual carriers of vaccine
and non-vaccine types, the instantaneous prevalence ratio of type
1 or group 1 pathogen, in the two  models is deﬁned as:
PR(t) = I
1
1(t)
I01(t)
× 1 − 

(SI-2model)
PR(t) = I
1
1(t) + I111(t)
I01(t) + I011(t)
× 1 − 

(SIS-2model) (4)
In the SI-2 model, we  consider two  possible scenarios: (i) vaccine
targets type 1, when type 1 is dominant, and (ii) vaccine targets type
1, when type 2 is dominant prior to intervention. These scenarios
are determined by the ratio of competition coefﬁcients ı = 1/2:
with type 1 dominance if ı < 1 and type 2 dominance viceversa.
When 1 = 2, the two  pathogen types stably coexist at equal abun-
dances. To explore type 1 dominance, in Fig. 3, we set 2 = 1 and
consider 1 between 0 and 1. To explore type 2 dominance by an
equal amount, we set 1 = 1 and vary 2.
In agreement with the SI-1 analysis (Fig. 2), the prevalence ratio
from the SI-2 model (Eq. (4)) is also most commonly higher than
the true relative risk w (Fig. 3). In addition, here we can see that
prevalence ratio is very sensitive to the relative magnitudes of com-
petition coefﬁcients, especially when the target strain is dominant.
For vaccines that target the dominant type we expect w to be over-
estimated (vaccine efﬁcacy under-estimated), by a larger amount
than for vaccines that target the non-dominant type. This indicates
the importance of using ﬂexible model formalisms that accommo-
date competition parameters to be estimated simultaneously with
vaccine efﬁcacy. From the ordering of the curves in this ﬁgure, we
can expect that using a model that ignores competition (1 = 2 = 1)
would generally lead to an overestimation of w (underestimation
of vaccine efﬁcacy) if type 1 is dominant in the real system, and the
opposite if type 2 is dominant.Intuitively, this can be understood by seeing the vaccine and
the intrinsic competitive interactions in the system as two forces
that affect the constituent strain dynamics. When type 1 is dom-
inant, and a vaccine targets type 1, the natural tendency of the
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Fig. 3. Prevalence ratio of target type in vaccinated and non-vaccinated hosts vs. true relative risk in the SI-2 model. Type 1 can be dominant prior to vaccination
(0.2  ≤ 1/2 ≤ 1), or alternatively, type 2 can be dominant (0.2 ≤ 2/1 ≤ 1). The coloured lines from blue to red correspond to increasing values of the competition ratio,
1/2 (above the red curve) and 2/1 from 0.2 to 1 (below the red curve). Although as time increases the prevalence ratio tends towards the parameter w, the value remains
biased  above due to competition between types in both cases, more so if type 1 is the better competitor. Other parameter values:  = 0.0167,  = 0.5. Vaccine targets type
1.  Different values of w are assumed in top/bottom panels: w = 0.5 and w = 0.3 respectively. Initial conditions at endemic equilibrium. Time is in units of years, where the
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overage  life expectancy is equal to 60 years. The low transmission cases (  ˇ = 0.032), 
or  the analogous ﬁgure with PR(t) taking into account mixed carriage I12 see Fig. S4
o  the web version of this article.)
ystem and the vaccine go in opposite directions, thus the sys-
em responds more slowly. When type 2 is dominant instead, the
accine targeting 1 and direct competition act in the same direc-
ion, and we expect faster propagation of vaccine effects in the
ntire system, whereby also the difference between vaccinated
nd non-vaccinated hosts emerges earlier (PR(t) → w faster post
accination).
In this model, competition affects also the convergence of POR
prevalence odds ratio) of type 1 pathogen to w. We  expect from the
quilibrium analysis of the SI-1 model, that POR(t) should be closer
o the true relative risk w than PR(t). This is what we ﬁnd. POR(t)
ends faster toward w after vaccination is in place in the SI-2 model.
owever, in the two-strain system with direct competition, POR(t)
s also affected by relative strain dominance (Fig. S2), although to
 lesser extent than PR(t), and depending on 1/2, it also may  not
lways reach asymptotically the true w.
In the SIS-2 model with 2 groups of pathogen types, we uncover
 regime where the prevalence ratio of aggregated pathogen types
argeted by the vaccine (in single and multiple carriage: I1 + I11)
n vaccinated vs. non-vaccinated hosts may  be below relative risk,
nd thus yield an over-estimation of vaccine efﬁcacy if it were to
e used for this purpose. This occurs for large transmission inten-
ity ˇ, and  close to 1 (Fig. 4). When  is small instead, the pattern
R(t) > w could persist indeﬁnitely. As  increases, there is initially
 downward bias if observations are made too soon after interven-
ion onset, and only after some time does PR(t) tend to the true
alue of relative risk. Depending on the exact magnitude of  ˇ and
, the deviation of relative prevalence ratio from w could persist for long time after the start of vaccination (Fig. S3). Indeed, as trans-
ission intensity increases, the prevalence of multiple carriage in
he host population increases, thus amplifying any indirect effects
f competition between types.
(pond to R0 = 1.9. While the high transmission cases (  ˇ = 0.32) correspond to R0 = 19.
interpretation of the references to colour in this ﬁgure legend, the reader is referred
Notice that the impact of competition hierarchies on prevalence
ratio PR(t) is very sensitive to how this prevalence ratio is deﬁned:
whether it takes into account or not, multiple mixed carriage of
1 and 2: I12. In Figs. S4 and S5, we  show the analogous scenarios
of Figs. 3 and 4, for a prevalence ratio that takes into account the
global FOI of target type(s), summing also the contribution I12/2 of
the mixed carriage host class. The sensitivity of PR(t) to competition
hierarchies, in this case decreases in the SI-2 model, and increases
drastically in the SIS-2 model, especially for high ˇ, with parallel
exacerbated deviation from w,  indicating that mixed carriage of
target and non-target types contributes more confounding from
indirect vaccine effects.
3.3. Using a dynamic model to infer vaccine efﬁcacy
As brieﬂy illustrated above, the use of prevalence ratios to assess
vaccine efﬁcacy presents four main problems:
(i) even in the best case of explicitly matching pre-vaccine and
post-vaccine equilibria (SI-1 model), thus even when satisfying
the stationarity assumption, the indirect transmission effects
mediated by the vaccine are typically confounded in the preva-
lence ratio of target types in vaccinated and non-vaccinated
individuals (subject to the interplay between R0 and vaccine
coverage);
(ii) in general for observational studies, the prevalence ratio is
dependent on the time of the survey post-vaccination, which
makes it non-robust and hard to compare or interpret across
settings, without mechanistically embedding time in the anal-
ysis;
iii) in polymorphic pathogen systems, prevalence-based indica-
tors can be biased depending on the magnitude and direction
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Fig. 4. Deviation of the prevalence ratio from true vaccine-induced protection in the SIS-2 model depends on transmission rate and the magnitude of competition. Higher
transmission intensity, leads to larger discrepancy in the immediate time scale after vaccine introduction. Fixed parameter values  = 0.02,  = 0.5,  = 0.6 and competition
coefﬁcient  = 1 and 0.5 respectively in the top, and bottom panels. Initial conditions at endemic equilibrium where both groups of types coexist at equal abundance. VE=50%
(dashed line depicts w = 1 − VE). The depletion factor effecting within-group coinfection  is varied between 0.1 and 0.9 (coloured lines from blue to red). Increasing overall
competition in the system makes indirect effects weaker, thus prevalence ratios reﬂect more accurately true relative risk w.  Time units are months, as here we consider a
childhood disease, and the mean age of hosts is 50 months. By type 1 we  refer to all pathogen types in group 1 targeted by the polyvalent vaccine. For the analogous ﬁgure
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of pre-existing competitive interactions between strains or
groups of strains, whose values are hard to know and factor
out a priori.
iv) in addition, in polymorphic systems shaped by competition
among strains, how the prevalence ratio of target types is
deﬁned in terms of single and multiple carriage of pathogen type
combinations is a critical determinant of the discrepancy with
true relative risk, as it is precisely the details of competition
at co-colonization that drive indirect effects of the vaccine,
especially at high transmission intensities.
Even if we were to use prevalence-odds- ratios (POR), instead
f prevalence ratios (PR), analysis could be inaccurate with regards
o estimating true relative risk (and hence vaccine efﬁcacy), as the
atch between these quantities generally applies only at equilib-
ium post-vaccine, and it is not exempt from bias introduced by
ampling time and competition hierarchies between strains.
Individual vaccine protection, in the dynamic transmission
odels (0 ≤ w ≤ 1) multiplies transmission rate (ˇ) and pathogen
revalence, thus it is naturally deﬁned per infectious contact. In
ontrast, the snapshot prevalence ratio, often reported in ﬁeld
tudies, misses the exposure dimension, being an output of the
verall dynamics with nonlinear and often non-trivial relation to
he original input parameter. To resolve these problems, a produc-
ive alternative is to use the full dynamic model, ﬁt it to prevalence
ata before and after vaccination, as obtained through cross-
ectional observational studies, thus estimating together several
ey epidemiological parameters. Based on pathogen prevalence
bservations, analysis of epidemiological studies post-licensure
ould factor out simultaneously the effects of multiple parameters:
, 1, 2 (within the SI-2 model) and ˇ, ,   (in the SIS-2 model),erences to colour in this ﬁgure legend, the reader is referred to the web  version of
in order to extract the true value of vaccine efﬁcacy (VE = 1 − w)
against the targeted types. Frequently, epidemiologists will have
enough information about the system to deﬁne the equations that
govern its behaviour, or test simultaneously competing appropri-
ate formulations. In our case, the parameters  and  (and  in the
SIS-2 model) are assumed known.
3.4. Numerical procedure for ODE model ﬁtting and parameter
inference
As a proof of concept, we  apply the following procedure. We
generate hypothetical data performing model simulations with
different parameter values, ﬁxing initial conditions at the pre-
vaccination endemic state. Observing the state of the system at
ti time units post-vaccination, subsequently we apply nonlin-
ear least-squares optimization (routine lsqnonlin in MATLAB) to
model-generated trajectories, in order to recover the underlying
parameters. Similar methodological approaches exist and are rou-
tinely applied to epidemiological data (e.g. in the context of R0
estimation Cintrón-Arias et al. (2009)). The error function (objective
function to be minimized) is given by:
Error =
∑
ti
∑
S,I1,I2 ...
(Theoretical model proportions(ti) − Data prevalences(ti))2,
(5)
where data may  be real or synthetically generated, as in our case
here. This estimation depends not only on ﬁtting the prevalence
of the pathogen types targeted by the vaccine, but also on the
prevalence of susceptibles, and of hosts infected with type 2, at spe-
ciﬁc time points post-vaccination in vaccinated and non-vaccinated
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Fig. 5. Bias in parameter estimation using the full epidemiological modelling framework. Dynamics with 100 random parameter combinations were simulated for each
model and the nonlinear least-squares optimization was performed on the reduced SI-2 type and SIS-2 system at a speciﬁc time post-vaccination. Fixed parameter values
were:   = 0.5,  = 0.0167 (SI-2) and  = 0.3,  = 0.02,  = 0.57 (SIS-2). Initial conditions were ﬁxed at endemic coexistence equilibrium in each model. Assuming imperfect
observations and a ﬁnite population size N = 1000, stochasticity was  implemented in the observation process by sampling hosts from a multinomial distribution at t = 0 and at
3  time-points post-vaccination (t1 = 12, t2 = 24, t3 = 36) which in the SI-2 model reﬂect ‘years’ and in the SIS-2 model reﬂect ‘months’. The models were ﬁtted to the resulting
‘synthetic’ sample proportions. In the bias boxplots (bias = 1 − (ˆ)/), the central mark is the median, the edges of the box are the 25th and 75th percentiles, the whiskers
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rxtend to the most extreme bias points not considered outliers, and outliers are plo
irect  competition coefﬁcients in the SI-2 model, while  denotes the competition
he  SIS-2 model.
osts. The errors are assumed to be normally distributed in this
ramework, but this assumption can be changed in more sophisti-
ated parameter estimation procedures.
Allowing for imperfect observations (in the synthetic data), real-
stic sampling error can be added to deterministic simulations. For
his, we draw host numbers in different compartments according
o a multinomial probability distribution, with probabilities from
rajectories of the ODE model (SI-2, SIS-2), and a given sample size
. By applying nonlinear least squares optimization to interpolate
uch synthetic sample prevalences generated after vaccination, we
an recover all the parameters of interest with very good accuracy
nd in an unbiased manner (Fig. 5).
A critical requirement for the sampling of prevalences post-
accination is that the sampling time-points are sufﬁciently spread
ver the interval [0, 1/], which is intuitive for a vaccine admin-
stered at birth, unless its implementation is preceded by a
igh-coverage vaccination campaign. In order to retrieve sufﬁ-
ient vaccine information, one has to follow the dynamics from the
nset of vaccination at least over the entire life-span of a typical
ndividual, i.e. over one generation. Provided this minimal range
equirement, the bias decreases further with sample size and withndividually.  ˇ denotes the transmission rate per unit of time, 1 and 2 denote the
cient and  the competition coefﬁcient corrected for within-group coinfection in
the number of time-points used to sample the population in the
post-vaccine era (Fig. 6).
In general, other advantages of deploying dynamic models over
more direct statistical descriptions of data, are that they can ﬁll the
gaps for unobserved intervals of system behaviour (Fig. 7), generate
new hypotheses, and yield more accurate predictions for the future.
3.5. The role of type-speciﬁc immunity and inference in a SIR
model
In the scenarios above, we restricted our attention to infections
with no immunity. In a separate model, we  extended the basic
SI-2 framework, to allow for type-speciﬁc immunity upon recov-
ery, all else kept equal, including vaccination against type 1 (see
Supplementary Text S2). When changing to an SIR-2 framework,
the baseline prevalence of infection in the pre-vaccine popula-
tion decreases for the same R0, and competition between types is
reduced. We  note that prevalence-ratio deviations from true vac-
cine efﬁcacy persist in the SIR-2 model, and get exacerbated by the
oscillatory nature of epidemiological dynamics of infections with
immunity (Fig. S6).
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Fig. 6. Bias decreases with number of sampling points and sample size N. Here, we show for the SI-2 model, how the mean (absolute) bias in parameter estimates across
different values ﬁtted through the dynamic model, varies with number of sampling time points and sample size. The ﬁrst time-point is taken at 12 time units post-vaccination,
and  the subsequent time points are taken in steps of 12. We assume  = 0.0167, corresponding to a life expectancy of 60 years and for vaccination coverage  = 0.5. The values
of   ˇ and 1, 2 are drawn randomly in the range [0.06, 0.32] and [0, 1], respectively, subject to the constraint of stable endemic coexistence prior to vaccination. As long as
the  sampling times cover the interval [0, 1/], information about the vaccine which is administered at birth can be extracted.
Fig. 7. Illustration of dynamic model ﬁtting to prevalence data in the SI-2 model. After vaccination against type 1 pathogen, cross-sectional prevalence data (circles) can be
integrated within a dynamic mathematical model (lines) to estimate epidemiological parameters, such as vaccine efﬁcacy and competition parameters between different
pathogen types. Here only overall prevalence of type 1 (blue line, ﬁlled circles) and prevalence of type 2 (red line, empty circles) are shown. Parameters used in this simulation:
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w = 0.3, w = 0.2, 1 = 0.1, 2 = 0.5 and  = 0.5,  = 0.0167 are ﬁxed. N = 1000 in (a
rror  to synthetic data. Applying the nonlinear least squares routine, in these parti
.108,  2 = 0.441 and (b)  ˇ = 0.416, w = 0.184, 1 = 0.059, 2 = 0.283. (For interp
ersion of this article.)
When applying dynamic model ﬁtting, we were able to infer
he parameters of interest ˇ, w, 1, 2, also for the SIR-2 model
rom prevalence observations post-vaccination. We  grouped ‘data’
nto: pathogen-free hosts (susceptible and immune), those carry-
ng type 1, type 2, and those carrying both 1 and 2. Under random
ampling effects (using the multinomial framework), even though
ransmission rate and vaccine efﬁcacy could be inferred accurately,
he quantiﬁcation of the direct competition coefﬁcients 1 and 2
as harder (Fig. S7). This is unsurprising, given the lower pathogen
revalence expected in the SIR-2 model, as a large proportion of
osts eventually become immune to both types and competition
nformation is lost. In fact, we expect that estimation of direct com-
etition parameters in a SIR framework requires larger sample sizes
nd more time-points, or a complete resolution of ODE variables
ith regards to host immune status and serological history. = 100 in (b) has been used in the multinomial sampling scheme to add sampling
instances, we have obtained these point estimates: (a)  ˇ = 0.297, w = 0.215, 1 =
on of the references to colour in this ﬁgure legend, the reader is referred to the web
Taken together, our simulations convey that in principle,
dynamic model ﬁtting through interpolating pre-vaccine and post-
vaccine pathogen prevalences can be used to retrospectively
assess vaccine effects in different host populations, under differ-
ent competition scenarios between target and non-target strains,
accounting for essential nonlinearities in transmission.
4. Discussion
In this study, we have suggested to close the gap between
mechanistic models of vaccine effects and statistical approaches
for estimation of vaccine efﬁcacy, addressing in addition multi-
type pathogens characterized by direct competition. One reason
for why mechanistic models have been somewhat neglected
in vaccine assessment studies, is that for validation, dynamic
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pidemiological models have to rely on spatiotemporally resolved
ata, and to date, epidemiological data tend to be static, and there-
ore more amenable to the tools of statistics. Yet, with increasing
nfrastructures and efforts to monitor health in populations over
ime, comes an opportunity to apply more dynamic frameworks
n the future, and match them with dynamic vaccine study
esigns.
.1. The importance and challenges of dynamic modelling
Here, we draw attention on a new application of mathemat-
cal models: namely, in the inference of vaccine efﬁcacy from
ross-sectional prevalence data, accounting for other critical deter-
inants of pathogen dynamics such as transmission rate, vaccine
overage, and competition between multiple types (Choi et al.,
011; Gjini et al., 2016). These data can be gathered from active
ampling and cross-sectional population surveys pre- and post-
accination, national screening programs after mass immunization,
r reported pathogen prevalence in different countries under spe-
iﬁc vaccination coverage rates.
We focused on scenarios of treatment effect homogeneity
leaky vaccine) and baseline homogeneity (no structure in the host
opulation), assuming randomization across vaccinated and non-
accinated hosts. Of course the models can be shaped so as to
ncorporate alternative scenarios, but this was beyond our scope
ere. Depending on the type of data that are available (e.g. if
revalence information is stratiﬁed by age, geography etc.), epi-
emiological models can include transmission between age groups
r different spatial locations (e.g. as in (Goeyvaerts et al., 2015)). The
pirit of inference remains the same; only in those cases one would
ave to specify contact parameters and feedbacks between differ-
nt sub-populations. In the current paper, the main structuring
imension was host vaccination status.
The need to modify current vaccine evaluation practices by
ncluding the exposure dimension in vaccine studies has been
ecently pointed out by Gomes et al. (2014), and additional
omputational frameworks are already emerging to estimate per-
xposure vaccine effects at the individual level (O’Hagan et al.,
014). Interpretation of vaccine efﬁcacy is inevitably entangled
ith context-speciﬁc epidemiological interactions and feedbacks.
hus, accurate quantiﬁcation of such individual protection param-
ter, which is robust, identiﬁable and comparable across settings,
an beneﬁt from inclusion of more mathematical approaches in
accine studies. Any length of post-vaccine follow-up period can
e interpreted within dynamic models, as long as the time-scale
f observations covers the typical host life-span interval [0, 1/],
specially in the case of SI and SIR dynamics, and as long as approx-
mations underlying model structure (e.g. homogeneous mixing)
re valid.
Notice, that the shortcoming of having to sample over an inter-
al of 1/ time-units to extract epidemiological parameters and
accine efﬁcacy, if necessary, can be dealt with through parame-
er inference procedures that extract baseline parameters such as
ransmission rate and competition coefﬁcients from ﬁtting analyt-
cal equilibrium expressions to prevalences pre-vaccination, and
hen using those estimates to project dynamics forward in the vac-
ine era. In that case, with already known coverage rate and known
aseline parameters, inference of vaccine efﬁcacy alone through
ynamic ﬁtting of prevalence observations over shorter time-scales
hould prove easier.
Depending on the transmission model, care must be taken with
egards to correlation between parameters. Some epidemiologi-
al quantities, e.g. total prevalence of target types, may  display
he same global magnitude at a given time post-vaccination, for
ery different parameter combinations (e.g.  and VE in the SIS-2
odel, shown in Fig. S8). However, if ﬁner-scale data are available,mics 14 (2016) 71–82
including stratiﬁcation with respect to host vaccination status
and single/multiple carriage, the apparently correlated parame-
ters can then be separated. This highlights the importance of high
resolution and high quality epidemiological data for parameter
estimation.
Here we  show that transmission rate and vaccine efﬁcacy
against targeted pathogen types can be robustly estimated by
dynamic model ﬁtting, even in the presence of observation error.
Yet, we also show that our power to identify direct competition
coefﬁcients from post-vaccine prevalence data may depend on the
overall level of pathogen prevalence in the population. Infectious
agents that display lower prevalence are likely to require larger
sample sizes in prevalence studies, for a correct resolution of their
diversity and inference of underlying subtype competition. This is
especially relevant in systems where hosts recover with immu-
nity. Lack of estimability of interaction coefﬁcients however does
not necessarily mean the model assuming those interactions is
invalid; rather it may  hint that those particular parameters are
not as important for the overall dynamics at the population scale
considered (Wikramaratna et al., 2014), or that a better resolu-
tion of host immunological status, besides simply carriage status, is
needed.
4.2. Vaccine efﬁcacy and effectiveness: linking trials and
population observations
Notice that while efﬁcacy is a direct parameter, that is easily
understood and can be averaged across settings, vaccine effec-
tiveness is a somewhat more subjective criterion: (i) it can be
deﬁned over a speciﬁc time post-vaccination, e.g. reduction in over-
all prevalence in the 3 years following vaccination; (ii) in the case
of multi-type systems, effectiveness can be deﬁned with regards
to carriage of the targeted pathogen types, or total carriage; (iii)
it can be deﬁned with regards to the vaccinated sub-population
only, or as an overall measure for the entire population irrespec-
tive of vaccination status; (iv) it can reﬂect disease manifestations
of the pathogen at the population level or asymptomatic carriage
states. All these ‘effectiveness’ indicators are important outputs
of the epidemiological dynamics, that can be calculated to meet
the demands of various policy-makers, and while they may  be
different, the intrinsic vaccine protection VE per individual is the
same.
When linking vaccine efﬁcacy against acquisition obtained
through randomized controlled trials pre-licensure, and the vac-
cine efﬁcacy estimated dynamically post-licensure, we  expect in
principle the two quantities should match. That is why  the frame-
work we propose could also serve as a validation test. Notice
however that often vaccine trials are conducted in one popula-
tion, while vaccines are implemented in another. Thus, differences
could arise. For example, interference with maternal antibodies
against local pathogens may  alter the vaccine protection against
other pathogens in a new vaccination programme. Immunological
responses may  also be inﬂuenced by nutrition status and other fac-
tors, thus there is nothing to preclude post-licensure assessment of
VE in populations where trials were not conducted in the ﬁrst place.
All these issues can be explored using dynamic models of transmis-
sion to interpret vaccination-induced changes in populations, and
extract the basic protection parameter. Even if the two quantities do
not match, one could argue that studying their discrepancy would
open the way  for better data collection, model improvement, ﬁne-
tuning of vaccination coverage, inclusion of host heterogeneities,
and ultimately a better understanding of the dynamics. Ideally, one
should work together with the two  approaches: both pre-licensure
and post-licensure, and try to match predictions with retrospec-
tive analyses. Although not primarily intended to address waning of
immunity, a dynamic framework is ideal to explore also the issue of
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he waning of vaccine-mediated protection, especially when inter-
olating prevalence observations over long intervals since the onset
f a vaccination programme.
A dynamic model, by its nature of mechanistically connect-
ng multi-dimensional epidemiological observations over time, can
xplain and link also more kinds of data, including the prevalence of
ultiple carriage, of competing pathogen types, and alterations in
revalence of total carriage over time. All these quantities could
ave implications for disease, for the evolutionary potential of
he pathogen, and interactions with other pathogens. A dynamic
odel thus offers a broader view of ‘effectiveness’. Predictions for
athogen dynamics in the population can be further integrated into
echanistic models for speciﬁc symptoms, as shown by Rodriguez-
arraquer et al. (2013).
.3. Methodological prospects
Our aims in this paper were illustrative and conceptual. For
his reason, we did not elaborate extensively on methodological
spects. Applying dynamic model ﬁtting within a Bayesian frame-
ork, to account for parameter uncertainty, is also possible. One
ould use the same objective function as in Section 3.4, or an
xplicit multinomial likelihood function, for the exact numbers of
osts observed in different epidemiological classes. In the latter
ase, the sample size N and expected probability vector coming
rom numerical integration of the ODE system with its set of param-
ters, would enter explicitly the likelihood term. Moreover, prior
nformation could be added about speciﬁc parameters, if available.
ne such Bayesian procedure is explained in detail, and applied
o a speciﬁc dataset on pneumococcus vaccination in Portugal, in a
elated paper by the authors (Gjini et al., 2016), where in addition an
nalysis of competing model formulations is undertaken. Another
mportant factor is process noise and stochasticity (Ellner et al.,
998; Shrestha et al., 2011). Parameter inference in mechanistic
odels based on systems of coupled ODEs is a timely and compu-
ationally challenging problem. Many advances in this respect are
eing made across ﬁelds such as statistics and computing (Haario
t al., 2006; Calderhead et al., 2009; Girolami and Calderhead, 2011;
ondelinger et al., 2013; King et al., 2014), and applied successfully
cross domains of science, including systems biology, astrophysics
nd climate studies. Reﬁnement of such methodologies for epi-
emiological models with vaccination should be straightforward
iven the multitude of tools that already exist or are in develop-
ent. The conceptual backbone of dynamic inference is likely to
pply across systems, however, challenges in speciﬁc diseases will
nevitably involve adaptation of model structure and reﬁnement of
he inference procedure.
Finally, there are many ways in which two pathogen strains can
ompete with each other, most notably via cross-immunity, which
e did not consider here. The existence of natural cross-immunity,
uch as among dengue (Adams et al., 2006; Wearing and Rohani,
006), or Human Papilloma Virus strains (Elbasha and Galvani,
005; Durham et al., 2012), poses the issue of eventual cross-
mmunity also in the vaccine-induced protection against particular
athogen types. To account for immune-mediated interactions,
odels need to specify how naturally acquired type-speciﬁc immu-
ity might interfere with vaccine-induced immunity (Gomes et al.,
004) and vaccine effectiveness (Omori et al., 2012). Robust infer-
nce of vaccine protection in these cases remains an open area for
uture research, calling for sophisticated vaccine study designs, as
o other factors, such as host population structure, secular trends
nd stochasticity. An accurate understanding of intervention effec-
iveness in populations under mass immunization will increasingly
equire integrated modelling frameworks for pre- and post-vaccine
ynamics, accounting for the interplay of all these factors.mics 14 (2016) 71–82 81
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.epidem.2015.11.
001.
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